Our Science

Rytvela is a first in-class IL-1 receptor peptide antagonist

Rytvela is a first in-class IL-1 receptor peptide antagonist addressing utero-placental inflammation (root cause of PTB) without affecting innate immunity unlike existing therapeutics. Rytvela reduces preterm birth in animal models and improves neonatal outcomes.

OIL-1 receptor antagonist rytvela

Unmet needs Rytvela IL-1 natural antagonist* PGF2a receptor inhibitors Hydroxy-
progesterone caproate** 		Oxytocin receptor inhibitor**
Addresses inflammation ✓ ✕ ✕ ✕ ✕
Reduces PTB ✓ ✓ ✓ ✕ ✓
Maintains innate immunity ✓ ✓ ✓ ✓ ✓
Improves neonate outcomes ✓ ? ? ✕ ✕

Why Rytvela is so efficient and promising to prevent preterm birth

1

Prevent inflammation

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor.
2

No side factors

In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo. Nullam dictum felis eu pede.
3

Development

Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. velit cursus nunc,
4

Results

orem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor.
5

Lorem Ipsum

Sed fringilla mauris sit amet nibh. Donec sodales sagittis magna. Sed consequat, leo eget bibendum.
6

Lorem Ispum

Sit back, relax and pop a cold one because your life just got a whole lot easier by using Salient.